Core Viewpoint - Avaà Bio and Austrianova have commenced the production of a Master Cell Bank for their Klotho anti-aging therapy, marking a significant step in their joint venture aimed at developing cell-based therapies for age-related disorders [1] Group 1: Company Developments - The Master Cell Bank (MCB) will consist of genetically modified cells that overexpress the -Klotho protein, which is essential for advancing the anti-aging product candidate within the ongoing -Klotho development program [1] - The establishment of the MCB is crucial for ensuring product consistency and reducing risks associated with contamination and genetic instability, thereby supporting a reliable supply chain for future therapies [1] - The MCB will serve as the primary source for all working cell banks, positioning the companies for long-term success in the production of innovative cell-based therapies [1] Group 2: Joint Venture Details - The joint venture, named Klothonova, was established in September 2025 and is equally owned by Avaà Bio and Austrianova's affiliate, SG Austria Pte. Ltd., focusing on sustainable production of the -Klotho protein [1] - The encapsulated cell product, Cell-in-a-Box®, will target age-related diseases such as Alzheimer's and cancer, while also advancing anti-aging treatments [1] - The production phase of -Klotho producing cells is seen as a commitment to delivering safe and effective treatments for aging-associated diseases [1]